Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study
Identifieur interne : 002B94 ( Main/Exploration ); précédent : 002B93; suivant : 002B95Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study
Auteurs : Yoshikuni Mizuno [Japon] ; Takashi Abe [Japon] ; Kazuko Hasegawa [Japon] ; Sadako Kuno [Japon] ; Tomoyoshi Kondo [Japon] ; Mitsutoshi Yamamoto [Japon] ; Mitsuyoshi Nakashima [Japon] ; Ichiro Kanazawa [Japon]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-10-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Activities of Daily Living (classification), Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Case-Control Studies, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Indoles (adverse effects), Indoles (therapeutic use), Levodopa, Levodopa (adverse effects), Levodopa (therapeutic use), L‐dopa, Male, Middle Aged, Mobility Limitation, Nervous system diseases, Neurologic Examination (drug effects), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Ropinirole, Treatment, Treatment Outcome, randomized controlled study, ropinirole, treatment.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Indoles, Levodopa.
- classification : Activities of Daily Living.
- drug effects : Neurologic Examination.
- drug therapy : Parkinson Disease.
- chemical , therapeutic use : Antiparkinson Agents, Indoles, Levodopa.
- Aged, Case-Control Studies, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Mobility Limitation, Treatment Outcome.
Abstract
We report the results of a randomized, double‐blind, placebo‐controlled, 16‐week study to evaluate the efficacy and safety of ropinirole, 0.75 to 15.0 mg/day, as an adjunct to levodopa. A total of 243 patients were randomly assigned into placebo or ropinirole groups. The mean (standard deviation) dose of ropinirole at endpoint was 7.12 (2.88) mg/day. The primary endpoint—the mean reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) total motor score—was significantly greater for the ropinirole group than the placebo group (−9.5 vs. −4.5, P = 0.00001). The mean reduction in the UPDRS total activities of daily living (ADL) score was also significantly greater for ropinirole than for placebo (−2.7 vs. −1.0, P = 0.0002). The percentage of patients showing at least a 20% reduction in the percentage of time spent “off” was significantly greater for the ropinirole group than for the placebo group (58.7% vs. 38.6%, P = 0.030). A total of 84.3 and 65.6% of the patients experienced adverse events while receiving ropinirole or placebo, respectively. The results showed that ropinirole was more effective than placebo in improving motor function and ADL when used as an adjunct to levodopa in patients with advanced Parkinson's disease. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21313
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001B01
- to stream Istex, to step Curation: 001B01
- to stream Istex, to step Checkpoint: 001702
- to stream PubMed, to step Corpus: 002594
- to stream PubMed, to step Curation: 002594
- to stream PubMed, to step Checkpoint: 002575
- to stream Ncbi, to step Merge: 001D65
- to stream Ncbi, to step Curation: 001D65
- to stream Ncbi, to step Checkpoint: 001D65
- to stream Main, to step Merge: 003B16
- to stream PascalFrancis, to step Corpus: 001517
- to stream PascalFrancis, to step Curation: 001802
- to stream PascalFrancis, to step Checkpoint: 001478
- to stream Main, to step Merge: 004068
- to stream Main, to step Curation: 002B94
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study</title><author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name></author><author><name sortKey="Abe, Takashi" sort="Abe, Takashi" uniqKey="Abe T" first="Takashi" last="Abe">Takashi Abe</name></author><author><name sortKey="Hasegawa, Kazuko" sort="Hasegawa, Kazuko" uniqKey="Hasegawa K" first="Kazuko" last="Hasegawa">Kazuko Hasegawa</name></author><author><name sortKey="Kuno, Sadako" sort="Kuno, Sadako" uniqKey="Kuno S" first="Sadako" last="Kuno">Sadako Kuno</name></author><author><name sortKey="Kondo, Tomoyoshi" sort="Kondo, Tomoyoshi" uniqKey="Kondo T" first="Tomoyoshi" last="Kondo">Tomoyoshi Kondo</name></author><author><name sortKey="Yamamoto, Mitsutoshi" sort="Yamamoto, Mitsutoshi" uniqKey="Yamamoto M" first="Mitsutoshi" last="Yamamoto">Mitsutoshi Yamamoto</name></author><author><name sortKey="Nakashima, Mitsuyoshi" sort="Nakashima, Mitsuyoshi" uniqKey="Nakashima M" first="Mitsuyoshi" last="Nakashima">Mitsuyoshi Nakashima</name></author><author><name sortKey="Kanazawa, Ichiro" sort="Kanazawa, Ichiro" uniqKey="Kanazawa I" first="Ichiro" last="Kanazawa">Ichiro Kanazawa</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DA94BA5E56393EC84EF1919AFCA6405AEC4DC84A</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21313</idno><idno type="url">https://api.istex.fr/document/DA94BA5E56393EC84EF1919AFCA6405AEC4DC84A/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001B01</idno><idno type="wicri:Area/Istex/Curation">001B01</idno><idno type="wicri:Area/Istex/Checkpoint">001702</idno><idno type="wicri:doubleKey">0885-3185:2007:Mizuno Y:ropinirole:is:effective</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17618525</idno><idno type="wicri:Area/PubMed/Corpus">002594</idno><idno type="wicri:Area/PubMed/Curation">002594</idno><idno type="wicri:Area/PubMed/Checkpoint">002575</idno><idno type="wicri:Area/Ncbi/Merge">001D65</idno><idno type="wicri:Area/Ncbi/Curation">001D65</idno><idno type="wicri:Area/Ncbi/Checkpoint">001D65</idno><idno type="wicri:doubleKey">0885-3185:2007:Mizuno Y:ropinirole:is:effective</idno><idno type="wicri:Area/Main/Merge">003B16</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:08-0015784</idno><idno type="wicri:Area/PascalFrancis/Corpus">001517</idno><idno type="wicri:Area/PascalFrancis/Curation">001802</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001478</idno><idno type="wicri:doubleKey">0885-3185:2007:Mizuno Y:ropinirole:is:effective</idno><idno type="wicri:Area/Main/Merge">004068</idno><idno type="wicri:Area/Main/Curation">002B94</idno><idno type="wicri:Area/Main/Exploration">002B94</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study</title><author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Juntendo University School of Medicine, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Abe, Takashi" sort="Abe, Takashi" uniqKey="Abe T" first="Takashi" last="Abe">Takashi Abe</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Iwate Medical University, Morioka</wicri:regionArea><orgName type="university">Université de médecine d'Iwate</orgName><placeName><settlement type="city">Morioka</settlement><region type="prefecture">Préfecture d'Iwate</region></placeName></affiliation></author><author><name sortKey="Hasegawa, Kazuko" sort="Hasegawa, Kazuko" uniqKey="Hasegawa K" first="Kazuko" last="Hasegawa">Kazuko Hasegawa</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, National Hospital Organization, Sagamihara National Hospital, Sagamihara</wicri:regionArea><wicri:noRegion>Sagamihara</wicri:noRegion></affiliation></author><author><name sortKey="Kuno, Sadako" sort="Kuno, Sadako" uniqKey="Kuno S" first="Sadako" last="Kuno">Sadako Kuno</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Clinical Research, National Hospital Organization, Utano National Hospital, Kyoto</wicri:regionArea><wicri:noRegion>Kyoto</wicri:noRegion></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, National Center of Neurology and Psychiatry, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Kondo, Tomoyoshi" sort="Kondo, Tomoyoshi" uniqKey="Kondo T" first="Tomoyoshi" last="Kondo">Tomoyoshi Kondo</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Wakayama Medical University, Wakayama</wicri:regionArea><wicri:noRegion>Wakayama</wicri:noRegion></affiliation></author><author><name sortKey="Yamamoto, Mitsutoshi" sort="Yamamoto, Mitsutoshi" uniqKey="Yamamoto M" first="Mitsutoshi" last="Yamamoto">Mitsutoshi Yamamoto</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, Kagawa Prefectual Central Hospital, Takamatsu</wicri:regionArea><wicri:noRegion>Takamatsu</wicri:noRegion></affiliation></author><author><name sortKey="Nakashima, Mitsuyoshi" sort="Nakashima, Mitsuyoshi" uniqKey="Nakashima M" first="Mitsuyoshi" last="Nakashima">Mitsuyoshi Nakashima</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Clinical Pharmacology, Hamamatsu Institute of Clinical Pharmacology and Therapeutics, Hamamatsu</wicri:regionArea><wicri:noRegion>Hamamatsu</wicri:noRegion></affiliation></author><author><name sortKey="Kanazawa, Ichiro" sort="Kanazawa, Ichiro" uniqKey="Kanazawa I" first="Ichiro" last="Kanazawa">Ichiro Kanazawa</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurology, National Center of Neurology and Psychiatry, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-10-15">2007-10-15</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="1860">1860</biblScope><biblScope unit="page" to="1865">1865</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">DA94BA5E56393EC84EF1919AFCA6405AEC4DC84A</idno><idno type="DOI">10.1002/mds.21313</idno><idno type="ArticleID">MDS21313</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living (classification)</term><term>Aged</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Case-Control Studies</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Indoles (adverse effects)</term><term>Indoles (therapeutic use)</term><term>Levodopa</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>L‐dopa</term><term>Male</term><term>Middle Aged</term><term>Mobility Limitation</term><term>Nervous system diseases</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Ropinirole</term><term>Treatment</term><term>Treatment Outcome</term><term>randomized controlled study</term><term>ropinirole</term><term>treatment</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Indoles</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Activities of Daily Living</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Indoles</term><term>Levodopa</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Case-Control Studies</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Mobility Limitation</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Lévodopa</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Ropinirole</term><term>Traitement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We report the results of a randomized, double‐blind, placebo‐controlled, 16‐week study to evaluate the efficacy and safety of ropinirole, 0.75 to 15.0 mg/day, as an adjunct to levodopa. A total of 243 patients were randomly assigned into placebo or ropinirole groups. The mean (standard deviation) dose of ropinirole at endpoint was 7.12 (2.88) mg/day. The primary endpoint—the mean reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) total motor score—was significantly greater for the ropinirole group than the placebo group (−9.5 vs. −4.5, P = 0.00001). The mean reduction in the UPDRS total activities of daily living (ADL) score was also significantly greater for ropinirole than for placebo (−2.7 vs. −1.0, P = 0.0002). The percentage of patients showing at least a 20% reduction in the percentage of time spent “off” was significantly greater for the ropinirole group than for the placebo group (58.7% vs. 38.6%, P = 0.030). A total of 84.3 and 65.6% of the patients experienced adverse events while receiving ropinirole or placebo, respectively. The results showed that ropinirole was more effective than placebo in improving motor function and ADL when used as an adjunct to levodopa in patients with advanced Parkinson's disease. © 2007 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Japon</li></country><region><li>Préfecture d'Iwate</li></region><settlement><li>Morioka</li><li>Tokyo</li></settlement><orgName><li>Université de médecine d'Iwate</li></orgName></list><tree><country name="Japon"><noRegion><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name></noRegion><name sortKey="Abe, Takashi" sort="Abe, Takashi" uniqKey="Abe T" first="Takashi" last="Abe">Takashi Abe</name><name sortKey="Hasegawa, Kazuko" sort="Hasegawa, Kazuko" uniqKey="Hasegawa K" first="Kazuko" last="Hasegawa">Kazuko Hasegawa</name><name sortKey="Kanazawa, Ichiro" sort="Kanazawa, Ichiro" uniqKey="Kanazawa I" first="Ichiro" last="Kanazawa">Ichiro Kanazawa</name><name sortKey="Kondo, Tomoyoshi" sort="Kondo, Tomoyoshi" uniqKey="Kondo T" first="Tomoyoshi" last="Kondo">Tomoyoshi Kondo</name><name sortKey="Kuno, Sadako" sort="Kuno, Sadako" uniqKey="Kuno S" first="Sadako" last="Kuno">Sadako Kuno</name><name sortKey="Kuno, Sadako" sort="Kuno, Sadako" uniqKey="Kuno S" first="Sadako" last="Kuno">Sadako Kuno</name><name sortKey="Nakashima, Mitsuyoshi" sort="Nakashima, Mitsuyoshi" uniqKey="Nakashima M" first="Mitsuyoshi" last="Nakashima">Mitsuyoshi Nakashima</name><name sortKey="Yamamoto, Mitsutoshi" sort="Yamamoto, Mitsutoshi" uniqKey="Yamamoto M" first="Mitsutoshi" last="Yamamoto">Mitsutoshi Yamamoto</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B94 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002B94 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:DA94BA5E56393EC84EF1919AFCA6405AEC4DC84A
|texte= Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study
}}
| This area was generated with Dilib version V0.6.23. |  |